Journal of Clinical Densitometry
Volume 12, Issue 2 , Pages 158-161 , April 2009

Variance in 10-Year Fracture Risk Calculated With and Without T-Scores in Select Subgroups of Normal and Osteoporotic Patients

  • Ronald C. Hamdy

      Affiliations

    • Osteoporosis Center, East Tennessee State University, Johnson City, TN, USA
    • VAMC, Johnson City, TN, USA
    • ,
  • Gary M. Kiebzak

      Affiliations

    • Center for Orthopaedic Research and Education, St. Luke's Episcopal Hospital, Houston, TX, USA
    • Corresponding Author InformationCorresponding author. Gary M. Kiebzak, Center for Orthopaedic Research and Education, St. Luke's Belmont Center, 2909 W. Holcombe Boulevard, Houston TX, 77025, USA.

Received 12 May 2008 ,Revised 1 December 2008 ,Accepted 1 December 2008.

References 

  1. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397
  2. Siris E, Delmas PD. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int. 2008;19(4):383–384
  3. Dawson-Hughes B, Tosteson AN, Melton LJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449–458
  4. Tosteson ANA, Melton LJ, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437–447
  5. Reginster J, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83–91
  6. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 2000;283(11):1424–1425
  7. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333(22):1437–1443
  8. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–2082
  9. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997;157(22):2617–2624
  10. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–645
  11. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–340

PII: S1094-6950(08)00508-8

doi: 10.1016/j.jocd.2008.12.003

Journal of Clinical Densitometry
Volume 12, Issue 2 , Pages 158-161 , April 2009

Article Tools